Currently there is a phase I clinical trial investigating the MAT2A inhibitor AG-270 in advanced solid tumors or lymphomas with homozygous deletions of CDKN2A/B or MTAP (NCT03435250). This evidence concerns the gene CDKN2A and lymphoma.